• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, January 24, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Older patients with Crohn’s disease benefit from new medications

Bioengineer by Bioengineer
March 20, 2019
in Chemistry
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Combining medications that suppress the immune system has been successful in treating young patients with Crohn’s disease, but some physicians have been reluctant to use this strategy in older patients because of concerns about safety. Now an Alimentary Pharmacology & Therapeutics study indicates that older patients can be safely and effectively treated with such combined immunosuppression as well.

Among the 1,981 patients in the study, 311 were aged 60 years or older (173 randomised to early combined immunosuppression and 138 to conventional management). Over 24 months, 10 percent of older patients developed Crohn’s disease?related complications (6.4 percent of those in the combined immunosuppression group versus 14.5 percent of those in the conventional management group) and 14 patients died (3.5 percent versus 5.8 percent).

Among the patients who received combined immunosuppression in the study, older patients experienced remission of their disease to a similar extent as those aged under 60 years. There was also no increase in side effects from these medicines in older patients.

“It is important to treat aggressive Crohn’s disease appropriately regardless of age,” said lead author Dr. Siddharth Singh, of the University of California San Diego. “This may include early step-up combination therapy of tumour necrosis factor-alpha antagonists with thiopurines, which is effective and safe even in older patients, rather than treating these patients with chronic or repeated courses of corticosteroids.”

###

Media Contact
Penny Smith
[email protected]
http://dx.doi.org/10.1111/apt.15214

Tags: cancerMedicine/HealthPharmaceutical SciencePublic Health
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

New Route to Strychnos Alkaloids via Thiophene Cycloadditions

January 23, 2026
Lithium Metal Powers Electrochemical PFAS Reduction Breakthrough

Lithium Metal Powers Electrochemical PFAS Reduction Breakthrough

January 20, 2026

Creating Synthetic Protein-Binding DNA Systems in Cells

January 17, 2026

Chiral Catalysis Powers Rotary Molecular Motors

January 16, 2026
Please login to join discussion

POPULAR NEWS

  • Enhancing Spiritual Care Education in Nursing Programs

    156 shares
    Share 62 Tweet 39
  • PTSD, Depression, Anxiety in Childhood Cancer Survivors, Parents

    148 shares
    Share 59 Tweet 37
  • Robotic Ureteral Reconstruction: A Novel Approach

    80 shares
    Share 32 Tweet 20
  • Digital Privacy: Health Data Control in Incarceration

    62 shares
    Share 25 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Exploring Misophonia Symptoms in Autistic Adults

Predicting Pulmonary Hemorrhage in Tiny Preemies

New SF3B1 Mutations Linked to Neurodevelopmental Disorders

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 71 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.